Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Mutual of America Capital Management LLC

Mutual of America Capital Management LLC lessened its holdings in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 2.1% in the third quarter, according to its most recent filing with the SEC. The firm owned 6,350 shares of the medical research company’s stock after selling 137 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Charles River Laboratories International were worth $1,251,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of CRL. Oregon Public Employees Retirement Fund lifted its holdings in Charles River Laboratories International by 1.0% in the second quarter. Oregon Public Employees Retirement Fund now owns 4,424 shares of the medical research company’s stock worth $914,000 after purchasing an additional 45 shares during the period. Empirical Finance LLC raised its position in shares of Charles River Laboratories International by 4.2% during the 3rd quarter. Empirical Finance LLC now owns 1,310 shares of the medical research company’s stock worth $258,000 after buying an additional 53 shares in the last quarter. American Trust lifted its stake in shares of Charles River Laboratories International by 5.9% in the 2nd quarter. American Trust now owns 976 shares of the medical research company’s stock worth $202,000 after acquiring an additional 54 shares during the period. Tortoise Investment Management LLC boosted its holdings in shares of Charles River Laboratories International by 77.0% in the second quarter. Tortoise Investment Management LLC now owns 131 shares of the medical research company’s stock valued at $27,000 after acquiring an additional 57 shares in the last quarter. Finally, OLD National Bancorp IN increased its stake in shares of Charles River Laboratories International by 3.1% during the third quarter. OLD National Bancorp IN now owns 1,988 shares of the medical research company’s stock valued at $392,000 after acquiring an additional 59 shares during the period. Institutional investors own 98.91% of the company’s stock.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, Director Richard F. Wallman sold 6,621 shares of the business’s stock in a transaction dated Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the transaction, the director now owns 12,386 shares in the company, valued at $2,676,862.32. The trade was a 34.83 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 1.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on CRL. Baird R W cut Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 8th. Evercore ISI boosted their price target on shares of Charles River Laboratories International from $190.00 to $225.00 and gave the stock an “in-line” rating in a research report on Thursday, November 7th. UBS Group upped their price target on shares of Charles River Laboratories International from $240.00 to $250.00 and gave the company a “buy” rating in a report on Thursday, November 7th. Barclays lowered their price objective on shares of Charles River Laboratories International from $230.00 to $210.00 and set an “equal weight” rating on the stock in a research note on Thursday, August 8th. Finally, CLSA lowered shares of Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 target price for the company. in a research note on Monday, November 18th. Three investment analysts have rated the stock with a sell rating, eleven have given a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, Charles River Laboratories International presently has a consensus rating of “Hold” and a consensus price target of $214.38.

Charles River Laboratories International Stock Performance

Shares of CRL stock opened at $201.16 on Tuesday. The company has a market capitalization of $10.29 billion, a price-to-earnings ratio of 25.18, a P/E/G ratio of 5.05 and a beta of 1.38. Charles River Laboratories International, Inc. has a 1-year low of $176.48 and a 1-year high of $275.00. The company has a current ratio of 1.48, a quick ratio of 1.14 and a debt-to-equity ratio of 0.61. The stock’s fifty day simple moving average is $194.94 and its 200-day simple moving average is $205.44.

Charles River Laboratories International (NYSE:CRL) last released its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.43 by $0.16. The company had revenue of $1.01 billion for the quarter, compared to analysts’ expectations of $975.99 million. Charles River Laboratories International had a return on equity of 14.29% and a net margin of 10.44%. The business’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same quarter in the previous year, the business posted $2.72 EPS. On average, sell-side analysts predict that Charles River Laboratories International, Inc. will post 10.19 earnings per share for the current fiscal year.

Charles River Laboratories International announced that its Board of Directors has approved a stock buyback plan on Wednesday, August 7th that permits the company to repurchase $1.00 billion in shares. This repurchase authorization permits the medical research company to buy up to 9.6% of its shares through open market purchases. Shares repurchase plans are generally an indication that the company’s board believes its stock is undervalued.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).